Gossamer Bio, Inc. (NASDAQ:GOSS – Get Rating) insider Richard Aranda sold 1,778 shares of Gossamer Bio stock in a transaction dated Wednesday, June 22nd. The stock was sold at an average price of $6.88, for a total value of $12,232.64. Following the sale, the insider now directly owns 209,897 shares in the company, valued at $1,444,091.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ GOSS traded up $0.29 during trading on Thursday, reaching $7.56. 563,411 shares of the company traded hands, compared to its average volume of 751,572. The company has a debt-to-equity ratio of 7.44, a quick ratio of 8.12 and a current ratio of 8.12. The stock’s 50 day moving average price is $7.43 and its two-hundred day moving average price is $9.02. The company has a market cap of $583.00 million, a price-to-earnings ratio of -2.44 and a beta of 1.11. Gossamer Bio, Inc. has a 1-year low of $5.64 and a 1-year high of $14.30.
Gossamer Bio (NASDAQ:GOSS – Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.01. Equities research analysts expect that Gossamer Bio, Inc. will post -2.73 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Walleye Capital LLC boosted its holdings in shares of Gossamer Bio by 39.2% in the 1st quarter. Walleye Capital LLC now owns 252,825 shares of the company’s stock worth $2,195,000 after acquiring an additional 71,201 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Gossamer Bio by 13.3% in the 1st quarter. Jane Street Group LLC now owns 31,691 shares of the company’s stock worth $275,000 after acquiring an additional 3,726 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Gossamer Bio in the 1st quarter worth approximately $1,429,000. Point72 Hong Kong Ltd acquired a new position in shares of Gossamer Bio in the 1st quarter worth approximately $33,000. Finally, Quantbot Technologies LP boosted its holdings in shares of Gossamer Bio by 11.3% in the 1st quarter. Quantbot Technologies LP now owns 13,801 shares of the company’s stock worth $119,000 after acquiring an additional 1,401 shares in the last quarter. 76.90% of the stock is currently owned by institutional investors and hedge funds.
About Gossamer Bio (Get Rating)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.
- Get a free copy of the StockNews.com research report on Gossamer Bio (GOSS)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.